

Radioimmunotherapy Using Oxide Nanoparticles

Disclosure Number

200401480

Technology Summary

Radioimmunotherapy (RIT) is an important approach to treating several non-solid tumor cancers or illness. The primary limitation of RIT is the unintentional release of the radionuclide or daughter products into normal tissues, causing radiotoxicity. This limitation is addressed through a novel nanoparticle delivery system, which guarantees containment of the radionuclide and daughter products, while still allowing efficient delivery of the radionuclide to targeted tissues as a monoclonal antibody (mAb) conjugate.

Inventor

DAI, SHENG

Chemical Sciences Division

Licensing Contact

SPEIGHT II, MELVIN D

UT-Battelle, LLC

Oak Ridge National Laboratory

Room 143, 4500N, MS: 6196

1 Bethel Valley Road

Oak Ridge, TN 37831

Office Phone: (865) 241-6564

E-mail: DSPEIGHT@ORNL.GOV

Note: The technology described above is an early stage opportunity. Licensing rights to this intellectual property may be limited or unavailable. Patent applications directed towards this invention may not have been filed with any patent office.